Skip to main content


Weitere Artikel dieser Ausgabe durch Wischen aufrufen

01.10.2015 | original article | Ausgabe 19-20/2015

Wiener Medizinische Wochenschrift 19-20/2015

EARLIER: an observational study to evaluate the use of cinacalcet in incident hemodialysis patients with secondary hyperparathyroidism in daily clinical practice

Wiener Medizinische Wochenschrift > Ausgabe 19-20/2015
Margit Hemetsberger, Rainer Oberbauer, Helmut Erb, OA Dr. Wolfgang Pronai
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s10354-015-0379-0) contains supplementary material, which is available to authorized users.


The EARLIER (Evaluation of MimpARa in incident hemodiaLysis patIEnts with secondaRy hyperparathyroidism; SHPT) observational postmarketing surveillance study evaluated incident hemodialysis patients (< 1 year dialysis vintage; n = 146) receiving cinacalcet in Austrian clinical practice. Despite intervention with vitamin D sterols and phosphate binders, 24 % had already developed severe SHPT (intact parathyroid hormone (iPTH) > 800 pg/mL) at baseline. After cinacalcet was started, median iPTH decreased substantially, from 611 pg/mL to 251 pg/mL (median decrease 58 % [IQR − 36 to − 78 %] at 12 months. Overall, 36 % of patients achieved the Kidney Disease Outcomes Quality Initiative (K/DOQI) target range (150–300 pg/mL) for iPTH; this included 35 % of those with severe SHPT at baseline. Serum phosphorus (P), calcium (Ca) (corr), and Ca (corr) × P also decreased, with 43, 34, and 62 % of patients, respectively, reaching K/DOQI targets at 12 months. Thus, in this observational study, mineral metabolism in incident dialysis patients with SHPT improved after starting cinacalcet.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Über diesen Artikel

Weitere Artikel der Ausgabe 19-20/2015

Wiener Medizinische Wochenschrift 19-20/2015 Zur Ausgabe